Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LVYMB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
6-Dec
|
|||||
| Synonyms |
DEC006; PTK7-CPT113; HWK-007
Click to Show/Hide
|
|||||
| Organization |
WuXi Biologics (Originator);Hangzhou DAC Biotechnology (DAC Biotech) (Originator);Whitehawk Therapeutics
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
(undisclosed)
|
|||||
| Antigen Name |
Inactive tyrosine-protein kinase 7 (PTK7)
|
Antigen Info | ||||
| Payload Name |
CPT113
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Highly stable yet cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Endometrial cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|